@OncEd Presents Dr. Jonathan Loree - Impact of Post-Operative Adjuvant Fluoropyrimidine Chemotherapy Following Pre-Operative Short Course radiotherapy in Stage II Rectal Cancer - Best f O...

@OncEd Presents Dr. Jonathan Loree - Impact of Post-Operative Adjuvant Fluoropyrimidine Chemotherapy Following Pre-Operative Short Course radiotherapy in Stage II Rectal Cancer - Best f O...

oncologyeducation

4 years
337 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Acute Lymphoblastic Leukemia
Description:
@OncEd Presents Dr. Jonathan Loree - Impact of Post-Operative Adjuvant Fluoropyrimidine Chemotherapy Following Pre-Operative Short Course Radiotherapy in Stage II Rectal Cancer - Best f Oncology West 2015
Up Next Autoplay
GRACE Supportive Care Series: Chemobrain with Guest, Lysa Buonnano
GRACE Supportive Care Series: Chemobrain with Guest, Lysa Buonnano
Category: Supportive Care
0 Views
cancergrace 12 hours
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: General
0 Views
Cancer-News 1 day
TOURMALINE-MM4: What's Next in Research?
TOURMALINE-MM4: What's Next in Research?
Category: Multiple Myeloma
0 Views
Cancer-News 1 day
TOURMALINE-MM4: Are There Safety Concerns?
TOURMALINE-MM4: Are There Safety Concerns?
Category: Multiple Myeloma
0 Views
Cancer-News 1 day
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Category: News
0 Views
ash 1 day
What should clinicians know about patients with the H3 K27M mutation?
What should clinicians know about patients with the H3 K27M mutation?
Category: Brain Cancer
0 Views
Massachusetts General Hospital 1 day
TOURMALINE-MM4: Regulatory Pathway
TOURMALINE-MM4: Regulatory Pathway
Category: Multiple Myeloma
0 Views
Cancer-News 1 day
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
Category: Brain Cancer
0 Views
Massachusetts General Hospital 1 day
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Category: Multiple Myeloma
0 Views
Cancer-News 1 day
ONC201 Recurrent Glioblastoma: How Can We Get Access to This Drug?
ONC201 Recurrent Glioblastoma: How Can We Get Access to This Drug?
Category: Brain Cancer
2 Views
Massachusetts General Hospital 1 day